In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...